Research Money Inc.

Opinion Leader: Canada’s early focus on artificial intelligence is starting to reap commercial benefits

Guest Contributor
November 16, 2021

Canada's early contributions and long-standing academic expertise in artificial intelligence are now generating growing funding for and revenue in AI in drug development, but the country's AI-enabled drug development industry faces significant challenges in coming years, Dr. Ulrik Kristensen, PhD, founder and principal analyst at UK-based Emersion Insights, says in an op-ed.

... Please become a Member or to read the rest of this article ...

Other stories mentioning these organizations, people and topics

Organizations:	AbCellera, Altis Labs, BenchSci, Cyclica, Deep Genomics, Emersion Insights, Government of Canada, Imagia, ProteinQure, SCALE AI, and WinterLight Labs
People:	Dr.(PhD) Ulrik Kristensen
Topics:	AI in drug development, artificial intelligence in Canada, challenges for Canada's AI drug development industry, global investment in AI in drug development, global market for AI in drug development, global revenue in AI in drug development, and Pan-Canadian Artificial Intelligence Strategy

Opinion Leader: Canada’s early focus on artificial intelligence is starting to reap commercial benefits

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

Opinion Leader: Canada’s early focus on artificial intelligence is starting to reap commercial benefits

Events For Leaders in Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

Events For Leaders in
Science, Tech, Innovation, and Policy